We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Endoscopic Approach Successfully Treats Pituitary Macroadenomas

By HospiMedica International staff writers
Posted on 13 Apr 2010
A new study shows that minimally invasive endoscopic procedures hold promise for safely removing macroadenomas, large tumors situated in the pituitary gland.

Researchers at the University of Cincinnati Neuroscience Institute (UCNI; OH, USA) conducted a retrospective study and analyzed the surgical outcomes of 27 consecutive patients who had undergone endoscopic removal of pituitary macroadenomas--tumors that are larger than 10 millimeters--between 2005 and 2007. More...
During surgery, unexpected residual tumors were searched for using intrasellar endoscopy, followed by a second examination via intraoperative magnetic resonance imaging (MRI).

The results showed that following the initial endoscopic tumor removal, intrasellar endoscopy revealed that 23 of the 27 patients (85%) had no unexpected residual tumor. Surgeons were able to perform safely additional surgery on three of the four patients who had unacceptable residual tumor tissue. Following completion of the endoscopic procedures, all patients were checked with intraoperative MRI, which revealed that tumor removal was successful in 26 of the patients (96%). The results, according to the researchers, show that maximum tumor removal can be successfully achieved with endoscopy and without intraoperative MRI. The findings were published in the April 2010 issue of the Journal of Neurosurgery.

"This signals the dawn of a new era in minimally invasive cranial surgery,” said lead author Philip Theodosopoulos, M.D., director of skull base surgery at UCNI. "We have moved from the realm of assessing whether it is feasible to studying its clinical effectiveness. In this way, it is slowly starting to change from a novelty to standard treatment, setting the bar for the quality of surgical outcomes higher than ever before.”

Although tumors of the pituitary gland, located near the base of the skull, are benign, pituitary macroadenomas can wreak havoc, causing acromegaly, Cushing disease, and hyperthyroidism, as well as visual problems, headaches, and dizziness. When removing pituitary macroadenomas, surgeons have employed three distinct routes to the tumor: via craniotomy, through an incision under the upper lip and then through the intranasal septum (which must be split apart), or via an endoscopic transsphenoidal approach, which follows natural anatomical corridors and causes less disruption of nasal tissues. Surgeons can ensure that the entire tumor has been removed using intraoperative MRI.

Related Links:

University of Cincinnati Neuroscience Institute




Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ultrasound Needle Guidance System
SonoSite L25
Bipolar Coagulation Generator
Aesculap
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.